Interestingly, for patient BC03, an actionable BRCA2 mutation might also indicate PARP inhibitors as a potential treatment choice in the relapsed lesion, as the cancer cell fraction of this mutation was 94.3% (Table 2). This evidence concerns the gene BRCA2 and cancer.